et al. Abstract CT169: a phase Ia study to evaluate RO7198457, an individualized neoantigen specific immunotherapy (iNeST), in patients with locally advanced or metastatic solid tumors. Cancer Res. 80, CT169 (2020). 23. Lopez, J. S.